BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 75,000 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 75,000 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $33.57, for a total value of $2,517,750.00. Following the transaction, the chief executive officer now owns 5,023,447 shares in the company, valued at approximately $168,637,115.79. This represents a 1.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Neil Kumar also recently made the following trade(s):

• On Wednesday, February 19th, Neil Kumar sold 31,543 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.14, for a total value of $1,139,964.02.
• On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28.

BridgeBio Pharma Stock Performance

Shares of NASDAQ BBIO traded up $0.85 during trading on Thursday, reaching $34.30. The stock had a trading volume of 4,057,719 shares, compared to its average volume of 3,190,594. The stock has a market cap of $6.52 billion, a PE ratio of -12.04 and a beta of 1.07. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $39.47. The firm’s 50 day moving average price is $32.35 and its two-hundred day moving average price is $28.17.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to analysts’ expectations of $4.04 million. On average, research analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Institutional Investors Weigh In On BridgeBio Pharma

A number of institutional investors have recently modified their holdings of BBIO. Polar Asset Management Partners Inc. bought a new position in BridgeBio Pharma in the third quarter worth about $1,286,000. First Turn Management LLC bought a new stake in shares of BridgeBio Pharma in the 3rd quarter worth approximately $10,178,000. Janus Henderson Group PLC lifted its holdings in shares of BridgeBio Pharma by 11.7% in the 3rd quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company’s stock worth $122,658,000 after purchasing an additional 505,481 shares during the last quarter. Intech Investment Management LLC acquired a new position in BridgeBio Pharma during the 3rd quarter valued at approximately $1,136,000. Finally, Principal Financial Group Inc. grew its stake in BridgeBio Pharma by 1.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company’s stock worth $29,155,000 after buying an additional 19,978 shares during the last quarter. Institutional investors own 99.85% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on BBIO shares. Bank of America upped their target price on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, November 25th. Citigroup upped their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Scotiabank lifted their target price on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Friday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $49.00 price target on shares of BridgeBio Pharma in a research note on Thursday, February 13th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $95.00 price objective on shares of BridgeBio Pharma in a research note on Friday, February 21st. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $51.67.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.